FDA Authorizes Lantheus’ Tau PET Imaging Agent for Alzheimer’s Disease Evaluation
As reported on Fierce BioTech, the U.S. Food and Drug Administration has granted approval to Lantheus’ positron emission tomography (PET) imaging agent Tauklarify (MK-6240), expanding diagnostic options for the assessment…
Continue Reading
FDA Authorizes Lantheus’ Tau PET Imaging Agent for Alzheimer’s Disease Evaluation
